Introduction {#Sec1}
============

Renal cell carcinoma (RCC) is a relative rare tumour type. It accounts for 2.1% of all malignancies and is responsible for 1.5% of all cancer deaths worldwide \[[@CR1]\]. Almost 25% of patients have metastatic disease at presentation, and 30--40% of patients that initially present with localized disease, develop metastases during the course of their disease \[[@CR2]\]. At that stage, patients cannot longer be cured, and 5-year survival rates do not reach 5% \[[@CR3]\]. Since chemotherapeutic and hormonal agents appeared to be of limited benefit, different treatment strategies have been developed \[[@CR4]\]. One frequently used strategy is immunotherapy with interferon-alpha (IFN-α) or combination therapy with IFN-α and interleukin-2 (IL-2) together with the biological agent 5-fluorouracil (5-FU).

Response assessment for these therapies has traditionally been made by anatomical imaging modalities, such as CT, using the Response Evaluation Criteria in Solid Tumors (RECIST) \[[@CR5]\]. These treatments, however, are rather cytostatic than cytoreductive, in which case successful treatment may not lead to a decrease in tumour size. An unchanged residual mass does not necessarily imply poor therapeutic response. This makes anatomical imaging less suitable for monitoring the effect of treatment strategies. Furthermore, differentiation between vital tumour and fibrosis or necrosis is difficult using morphological imaging. Therefore, functional imaging techniques to monitor response to therapy may be an attractive alternative to morphological imaging. Positron emission tomography (PET) with ^18^fluorodeoxyglucose (FDG) is an imaging modality, which has already an established role for many indications in clinical oncology \[[@CR6], [@CR7]\]. With PET, using the fluoride-18-labelled glucose analogue FDG, tissue with a high-glucose metabolic rate is visualized, which is useful for initial diagnosis or staging. Furthermore, quantification and measurement of therapy-induced changes in glucose metabolism is possible with PET as well.

Earlier studies on FDG-PET for evaluation of malignant lymphoma after chemotherapy show that FDG-PET was superior to CT in predicting progression-free survival \[[@CR8], [@CR9]\]. Similar results were found in recent studies in patients with non-small cell lung cancer and colorectal cancer in which chemotherapeutic response was evaluated with FDG-PET \[[@CR10], [@CR11]\].

Furthermore, FDG-PET has also shown to be useful in monitoring the response to targeted therapy in various malignancies as for instance malignant gastrointestinal stromal tumours \[[@CR12]\]. Concerning immunotherapy, promising results have been obtained from recent studies on response evaluation with FDG-PET in patients with non-Hodgkin lymphoma with suggestion of superiority to CT as well \[[@CR13], [@CR14]\].

In this study, we investigated whether FDG-PET is a useful modality for monitoring therapeutic response and for predicting outcome in terms of survival and progression-free survival in patients who were treated by either IFN-α monotherapy or triple therapy with IFN-α, IL-2 and 5-FU. Quantitative FDG-PET analysis using glucose metabolic rate (MR~Glu~) was compared with conventional CT imaging using RECIST. Survival and progression-free survival served as the standard of reference.

Materials and methods {#Sec2}
=====================

Patients {#Sec3}
--------

The present study was carried out as part of a large multicenter protocol that studied the therapeutic effect of IFN-α, IL-2, 5-FU triple therapy compared with IFN-α-monotherapy on advanced stages of RCC. All patients considered eligible for this multicenter trial (Table [1](#Tab1){ref-type="table"}) were asked to participate in this side study. An exclusion criterion for the side study was diabetes mellitus. Patients participating in the multicenter trial were randomized for treatment with IFN-α monotherapy or triple therapy including IFN-α, IL-2 and 5-FU.Table 1Inclusion criteria multicenter trialDisease characteristics Histological confirmed renal cell carcinoma Advanced metastatic disease that requires treatment No brain metastasesPrior/concurrent therapy No prior biological therapy No prior chemotherapy No prior endocrine therapy At least 4 weeks since prior radiotherapy Prior resection of the primary tumour recommended but not required No prior major organ allograftsPatient characteristics Age 18--81 years Performance status WHO 0--1 Life expectancy of more than 12 weeks WBC greater than 3,000/mm^3^ Platelet count greater than 100,00/mm^3^ Haemoglobin greater than 10 g/dL No myocardial infarction within the past 6 months No unstable angina pectoris Not pregnant or nursing Female patients must use effective contraception during and for at least 6 months after study participation No other current disease or prior malignancy that would preclude study treatments or comparisons No current active infection requiring antibiotics

FDG-PET {#Sec4}
-------

FDG-PET was performed prior to treatment and respectively after 5 and 9 weeks for response evaluation (Table [2](#Tab2){ref-type="table"}). Patients were fasted for at least six hours prior to injection of 200 MBq ^18^F-FDG. FDG-PET was performed on an ECAT-EXACT47 PET scanner (Siemens/CTI, Knoxville, TN, USA). Patients were positioned supine. The dynamic data acquisition was started simultaneously with the injection of FDG.Table 2Treatment and evaluation: patients were treated either with triple combination therapy consisting of IFN-α, IL-2 and 5-FU or IFN-α-monotherapyWeekDayIFN-α (MU/m^2^)IL-2 (MU/m^2^)5-FU (mg/m^2^)IFN-α (MU)Baseline FDG-PET-scan 1165310541051010 2--3165103651056510 416103101041051010First evaluation FDG-PET-scan197501039105910 6--8197501039105910Second evaluation FDG-PET-scan*FDG*-*PET* was performed at baseline, in week 5 and week 9

Tumour time-activity curves {#Sec5}
---------------------------

Tumour time-activity curves were obtained by placing volumes of interest (VOIs) semi-automatically over the tumour and metastases using a threshold of 50% of the maximum pixel value within the lesion. The locations of the lesions were evaluated visually on the transaxial, coronal and sagittal images. For this purpose, the late frames (frame 14--16) were summed, yielding a static image of 30 min and a scan mid-time of 35 min post-injection. The tumour VOIs were then copied to all dynamic time frames to obtain time--activity curves. A volume-weighted mean value of all lesions in each PET scan was derived to provide one MR~Glu~ for each study.

Image-derived input function {#Sec6}
----------------------------

The image-based input functions were determined by measuring FDG counts in VOIs over the ascending aorta or abdominal aorta, depending on the body location of the study. An early time frame (frame 3, i.e., 60--90 s post-injection) was used, in which the bolus of activity was best visualized, and time-activity curves were created using VOIs that consisted of several regions of interest drawn over the blood pool area in as many planes as possible. For VOI definition, a semi-automatic threshold-based region-growing programme was used. All VOIs were confirmed visually \[[@CR15]\].

Patlak graphical analyses {#Sec7}
-------------------------

For quantitative measurement of glucose metabolism, Patlak graphical analysis was used to calculate the MR~Glu~ (expressed in μmol ml^−1^ min^−1^) in tumour tissue \[[@CR16]\]. The Patlak approach takes into account differences in the whole-body distribution of FDG at the time of scanning, which may affect the accumulation of FDG in the tumour tissue. Therefore, the MR~Glu~ is in principle a more reliable measure of tumour glucose use than the standardized uptake value (SUV). Patlak graphical analysis is based on the assumption that the ratio of the tracer concentration in tissue to that in plasma increases linearly when plotted as a function of normalized time. This linear relationship follows directly from the FDG model when the free tissue FDG concentration is constant and unidirectional transport, i.e., trapping of FDG can be assumed. This assumption in practice occurs about 5 min post-injection. The Patlak analysis was performed over the period from 5 to 50 min after injection. Furthermore, the MR~Glu~ (expressed in μmol ml^−1^ min^−1^) in tumour was calculated by multiplication of the slope of the Patlak-plot (K~1~k~3~.(k~2~ + k~3~)^−1^) and the basic blood glucose level (expressed in μmol ml^−1^), measured before FDG injection (hexokinase method, Aeroset, Abbott diagnostics, Illinois, USA). In this study the lumped constant used was set to 1 and was assumed to be constant over time, because no studies on the actual value of the lumped constant in tumours outside the central nervous system have been reported yet.

Patient evaluation and follow-up {#Sec8}
--------------------------------

The first response evaluation PET was performed after five weeks when immunotherapy with IL-2 in the triple-therapy-group was completed and therapy with 5-FU was not yet started. Furthermore, patients treated with IFN-α monotherapy were maximally boosted at that time. The second evaluation at nine weeks was chosen because of the concurrent CT evaluation at that time-point, in order to obtain more comparable results. Data derived from the Patlak analysis were compared with those from CT-response evaluation based on RECIST guidelines \[[@CR5]\].

Clinical follow-up took place at 9, 19 and 26 weeks, at 8, 10 and 12 months, subsequently every 4 months for 1 year and every 6 months thereafter. In this follow-up period, CT was used to determine response. The median follow-up period was 37.5 months (range 22--47 months).

Progression-free survival was defined as the duration of response/stable disease as determined by CT, starting from the day on which the baseline PET was performed. Overall survival was defined as the time from baseline PET until death.

Statistical considerations {#Sec9}
--------------------------

When designing the study, a power analysis was performed to estimate the required size of the patient population. Data from the literature suggest that 15% of patients show response on immunotherapy and 30% of patients show stable disease according to RECIST \[[@CR17]\]. Conventional imaging, however, often underestimates immunotherapy treatment response. Thus, to detect 20% more treatment responses using FDG-PET, a sample size of 15 patients is required (alpha 0.05, power 0.80, McNemar test, two-sided), assuming that PET does not underestimate therapy response.

An agreement was made to perform an interim analysis halfway the study and to discontinue if the interim analysis would not show an association between metabolic and morphologic response assessment or (progression-free) survival.

Results {#Sec10}
=======

FDG-PET was performed in 7 patients with metastatic RCC. All patients were nephrectomized (6 men, 1 woman; mean age 59 years; range, 49--66 years) and had histologically confirmed RCC, all of the clear cell type. Four patients already had metastatic disease at initial diagnosis. Metastases were located in the lung, lymph nodes and adrenal gland. The median follow-up period was 37.5 months (range, 22--47 months).

Two patients received triple therapy, and five were treated with IFN-α monotherapy. According to CT, performed 9 weeks after starting therapy, one patient had partial response, four had stable disease, and two had progressive disease. Complete remission was not observed. The median progression-free survival after starting immunotherapy was 9 months (range, 3--37 months). Four patients died, all within 40 months after initial diagnosis.

The average glucose metabolic rate measured at baseline was 0.0665 μmol/ml/min (range, 0.0365--0.1028). There was a large variation of glucose metabolic rate within the group of patients. No association between metabolic and morphologic response, progression-free survival and overall survival was found at interim analysis (Fig. [1](#Fig1){ref-type="fig"}), which resulted in a discontinuation of the study.Fig. 1Metabolic rate of glucose of each response group, measured at baseline (MR~Glu~1) and after 5 and 9 weeks of treatment (MR~Glu~2 and MR~Glu~3 respectively). Therapy consisted of either IFN-α (*straight line*) or triple therapy (*dashed line*). Response groups were defined as partial response (**a**), stable disease (**b**) and progressive disease (**c**) according to RECIST on CT findings. No association between glucose metabolic rate and response to therapy, as established by CT, and progression-free survival (PFS) and overall survival (OS) was found

Discussion {#Sec11}
==========

At present, response monitoring of antitumour treatments with FDG-PET is still in its infancy. Not for all kinds of antitumour treatment it is elucidated whether FDG-PET is capable of predicting response and whether FDG-PET shows added value in response evaluation of a certain treatment. The present study, however, could not confirm the utility of FDG-PET-based response evaluation of immunotherapy in patients with metastatic RCC.

In the present study, the variable metabolic response pattern on immunotherapy without correlation to morphological response and overall survival or progression-free survival may be explained by some biological features of RCC tumour cells and by the effect of immunotherapy on these biological features. One could speculate, on the possible effects on glucose metabolism of the hypoxia inducible factor 1α (HIF-1α), activated T cells and the expression of c-myc in RCC.

The latter one is a proto-oncogene that regulates cell proliferation, cell growth and apoptosis. Evidence for over-expression in c-myc in most cases of RCC has been found and is correlated with T status, nuclear grade and venous invasion. However, the expression of c-myc, which variates within patients with RCC, is not correlated with clinical parameters such as nodal or distant metastasis, tumour type and neither is an independent predictor of survival \[[@CR18]\]; consequently, IFN-α is not equally effective in each patient.

It is known that c-myc enhances glucose metabolism \[[@CR19]\]. In case of such a straightforward relation, one would expect some correlation between (progression-free) survival, morphological response and the degree of MR~Glu~ prior to therapy. However, this was not seen in the present study. This suggests more unknown mechanisms that interfere with glucose metabolism as for instance HIF-1α over-expression which is associated with loss of functional Von Hippel-Lindau (VHL) gene which occurs in approximately 70% of clear cell RCCs \[[@CR20]\]. HIF-1α over-expression in RCC is also associated with high GLUT-1 expression \[[@CR21]\].

Furthermore, in the two patients who were treated with triple therapy, activation of T cells by IL-2 could also have contributed to an enhancement of glucose metabolism after therapy as well. In this case, an increment in MR~Glu~ due to inflammatory reaction could mask a true therapeutic effect.

On staging of RCC and in the preoperative diagnostic work-up, far more studies concerning the role of FDG-PET have been published. For instance, Kang and colleges investigated a group of 66 patients with renal cell carcinoma. Although the specificity of FDG-PET was 100%, which was superior to CT, sensitivity was low for both primary and metastatic lesions (60 and 77%, respectively) due to variation in FDG avidity of these tumours \[[@CR22]\].

It remains unclear why FDG uptake (glucose metabolism) varies among patients with RCC. In some malignancies, FDG uptake is correlated with glucose transporter protein 1 (GLUT-1) expression \[[@CR23], [@CR24]\]. No evidence for such a correlation in RCC, however, has been found \[[@CR25]\]. In our group of patients with metastasis who had resection of the primary tumour, glucose metabolic rate prior to immunotherapy varied widely as well.

Finally, there are more radiopharmaceuticals for PET beyond FDG. The goal of more targeted, individualized therapies probably needs more specific, biologically directed imaging, a role for which PET is ideally suited. Future applications of PET for therapy response assessment will likely involve other tracers in addition to FDG, to better characterize tumour biology and more effectively measure response to antitumour therapy, such as immunotherapy. New PET tracers for imaging RCC, like ^18^F-fluoromisonidazole (^18^F-FMISO), ^11^C-acetate and ^89^Zr-labelled cG250 monoclonal antibody already have been investigated with promising results \[[@CR26]--[@CR28]\]. However, these studies all focussed on staging and on imaging the primary RCC prior to therapy.

Conclusion {#Sec12}
==========

In contrast to the positive results reported on (chemo) therapy response evaluation in a wide variety of malignancies, FDG-PET seems not to be useful for response monitoring of immunotherapeutic modalities in RCC.
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